Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer

a technology of ductal epithelium and cancer, which is applied in the direction of phosphorous compound active ingredients, dsdna viruses, peptide/protein ingredients, etc., can solve the problems that the current method of prophylactic mastectomy is limited to physical monitoring and treatmen

Inactive Publication Date: 2006-12-28
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
View PDF24 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach effectively inhibits cancer formation and spread by selectively destroying ductal epithelial cells, offering a less invasive and more effective prophylactic and therapeutic treatment for breast cancer with reduced side effects.

Problems solved by technology

Cancers of exocrine glands pose a major health problem, frequently resulting in death.
In spite of the recent discovery of the heritable breast cancer susceptibility loci, BRCA1 (Miki et al., Science 266:66-71 (1994)) and BRCA2, and other cancer susceptibility loci, and the increasing ability of physicians to identify women with elevated breast cancer risk, prophylactic methods are still currently limited to physical monitoring and prophylactic mastectomy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0041] This example demonstrates the successful delivery of virus and other agents into the mammary ductile tree by a single injection through the teat.

[0042] ADV / CMV-β-gal (from Dr. William Burns, Johns Hopkins University) is an adenoviral 5 vector constructed with a 13-galactosidase gene controlled by a cytomegaloviral promoter. It was delivered into the mammary gland by injection of a viral suspension in 20 μl of 0.2% trypan blue in Tris buffer through the teat of a rat. The nipple was extruded, and the sphincter removed by excising the nipple. In the rat, the muscle prevents fluid from regurgitating into the breast and had to be excised in order to visualize the ductal opening and administer the agent. Trypan blue was used as a tracking dye to ensure correct delivery to the ductile tree. Injection about 30 days postpartum resulted in the mammary epithelial tree being clearly visible. Ethyl alcohol (70%) was also successfully delivered by a single injection through the teat.

example 2

[0043] This example demonstrates that adenovirus can efficiently transduce human mammary epithelial cells in vitro.

[0044] ADV / CMV-β-gal was used to transduce HBLIOO mammary epithelial cells in vitro. The β-gal enzyme in this construct contains a nuclear localization signal and results in dense nuclear staining .HBL100 cells (102) were plated in 24-well plates, and transduced with virus at various doses and stained with X-gal 48 hrs later. Essentially all cells were infected at a moi=104.

[0045] This experiment also has been performed in human mammary tumor cells MCF-7 (American Type Culture Collection (ATCC), Rockville, Md.), human mammary epithelial cells MCF-10A (ATCC), and two rat mammary cancer cell lines, RBA (from Dr. Leonard Cohen) and 37-2 (from Dr. C. Marcelo Aldaz) with the same results. More efficient adenoviral constructs have been used, thereby achieving 100% infection at a moi=103. These experiments demonstrate successful infection by and expression of adenovirus carr...

example 3

[0046] This example demonstrates that infection with an AdHS-tk construct followed by GCV treatment effectively kills mammary tumor cells in vitro.

[0047] RBA and NMU68 are two rat mammary tumor cell lines derived from a DMBA- and a NMU-induced tumor, respectively [DMBA=dimethylbenz [a] anthracene, NMU=N′-nitro N′-methylurea]. Each cell line was plated at a density of 5×102 in 48-well plates (1.1 cm) and allowed to settle overnight. The next morning, they were transduced with AdHS-tk (Chen et al., PNAS (USA) 91:3054-57 (1994); obtained from S. Woo and E. Aguilar-Cordova, Baylor College of Medicine, Houston, Tex.) at titers of 0, 100, 500, and 1000 moi, and then, 6 hrs later, GCV (10 pg / ml) was added to the culture media. The cells were maintained in the presence of GCV for 3 days and then counted using trypan blue exclusion as a measure of cell viability. The cell numbers were normalized to the growth of cells in the absence of GCV. The results are shown in FIG. 1. More than 80% of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular a mammary gland, for disease, in particular cancer. The methods comprise contacting the ductal epithelium of the exocrine gland with an epithelium destroying agent, preferably by ductal cannulation, so as to realize a prophylactic or therapeutic effect.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a Continuation of application Ser. No. 11 / 179,322, filed Jul. 12, 2005, which is a Divisional of application Ser. No. 09 / 971,901, filed Oct. 5, 2001 (now U.S. Pat. No. 6,932,777), which is a Divisional of application Ser. No. 09 / 240,206, filed Jan. 29, 1999 (now U.S. Pat. No. 6,330,472), which is a Continuation of application Ser. No. 09 / 093,145, filed Jun. 8, 1998 (now U.S. Pat. No. 6,153,184), which is a Divisional of application Ser. No. 08 / 692,001, filed Aug. 2, 1996 (now U.S. Pat. No. 5,763,415), which claims benefit of application No. 60 / 028,929, filed Aug. 3, 1995, the entire contents of which are incorporated herein by reference.STATEMENT OF GOVERNMENT SUPPORT [0002] The invention disclosed in this application was made with government support under NIH planning grant P20 CA / ES66205, “Gene-mediated prevention of Cancer,” and grant NIH 1RO1 CA 57993, “Genetic and hormonal factors in mammary carcinogenesis,” awa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K38/19A61K31/7072A61K31/704A61K31/663A61K31/525A61K31/522A61K31/337A61K31/505A61K31/513A61K35/76A61K38/45A61K48/00
CPCA61K31/337A61K31/505C12N2710/24132C12N2710/10332A61K48/00A61K31/513A61K31/522A61K31/525A61K31/663A61K31/704A61K31/7072A61K35/76A61K38/193A61K38/45A61K2300/00
InventorSUKUMAR, SARASWATI VAIDYANATHAN
OwnerTHE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE